What is the current stock price of Ironwood Pharmaceuticals, Inc. (IRWD)?

As of the latest market data, Ironwood Pharmaceuticals, Inc. (IRWD) is trading at $3.71. The stock has seen a loss of -4.87% today.

Does Ironwood Pharmaceuticals, Inc. (IRWD) pay a dividend?

Based on current data, Ironwood Pharmaceuticals, Inc. does not have a confirmed active dividend policy.

What is the market cap of Ironwood Pharmaceuticals, Inc.?

The current market capitalization of Ironwood Pharmaceuticals, Inc. (IRWD) is approximately unavailable.

IRWD

Ironwood Pharmaceuticals, Inc.·Healthcare

3.71

4.872%(−0.19)

Close Price

3.74

0.809%(+0.03)

Pre-Market

Last Updated: — ET

52W L: $0.5652W H: $5.78

IRWD NEWS

gurufocus.com

21h ago

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

[url="]Ironwood Pharmaceuticals, Inc.[/url] (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living wi

businesswire.com

21h ago

FDA Approves Use of LINZESS® (linaclotide) in Pediatric Patients Two Years of Age and Older with Functional Constipation (FC)

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved the use of LINZESS® (linaclotide) in pediatric patients 2 years of age and older with functional constipation (FC). LINZESS was previously approved for pediatric patients 6 years and older with FC. With thi.

seekingalpha.com

6d ago

Ironwood Pharmaceuticals: A Contrarian Buy Opportunity

Ironwood Pharmaceuticals presents a contrarian buy opportunity after a 14.5% decline driven by CFO resignation and insider selling. At the current $3.49 quote, IRWD fundamentals remain intact, supported by an SA Quant STRONG BUY rating and a base-case target of $6.90, implying ~100% upside. Short-term volatility is attributed to management changes and insider sales, but underlying cash generation and business model remain intact.

seekingalpha.com

May 13

Ironwood Pharmaceuticals: CFO Resignation Knocks Shares - A Downgrade Is Due

Ironwood Pharmaceuticals is downgraded to Hold after the CFO's resignation and despite record Q1 2026 Linzess-driven revenues. IRWD guides for $1.125–$1.175bn in Linzess sales and $450–$475m in total revenues in 2026 but faces 2027 Medicare price cuts and 2029 generic entry. Apraglutide's Phase 3 confirmatory trial launches in 2026, but competitive and regulatory hurdles cloud its $700m peak sales potential.

marketbeat.com

May 8

Ironwood Pharmaceuticals Q1 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported a strong start to 2026 and reiterated its full-year outlook, pointing to sharp first-quarter growth for LINZESS and continued progress toward a confirmatory phase III program for apraglutide in short bowel syndrome with intestinal failure (SBS-IF).

zacks.com

May 8

Ironwood Stock Down Despite Q1 Earnings and Revenue Beat

IRWD beats Q1 earnings and revenue estimates with Linzess sales surging on strong demand, but shares slide despite better-than-expected results.

Company Profile

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Employees

253

IPO Date

2010-02-03

Beta

0.30

Websitewww.ironwoodpharma.com↗